Amgen Provides Update On Status Of Parsabiv™ (Etelcalcetide) New Drug Application (NDA) Submitted To The U.S. Food And Drug Administration (FDA)
Go back to Amgen Provides Update On Status Of Parsabiv™ (Etelcalcetide) New Drug Application (NDA) Submitted To The U.S. Food And Drug Administration (FDA)| Amgen Inc (NASDAQ: AMGN) | Delayed: 342.98 +5.38 (1.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $337.60 | 52 Week High | $176.85 | |||
| Open | $337.65 | 52 Week Low | $133.64 | |||
| Day High | $345.11 | P/E | 51.65 | |||
| Day Low | $337.60 | EPS | $6.64 | |||
| Volume | 1,164,283 | |||||
